These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 16757249

  • 1. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
    Iaria G, Pisani F, Iorio B, Lucchesi C, De Luca L, Ielpo B, D'Andria D, Tariciotti L, Tisone G.
    Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249
    [Abstract] [Full Text] [Related]

  • 2. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M, Wasler A, Prenner G, Stiegler P, Stadlbauer V, Schwarz M, Tscheliessnigg K.
    Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
    [Abstract] [Full Text] [Related]

  • 3. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
    Tedesco-Silva H, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, Civati G, Campbell S, Alves-Filho G, Bourbigot B, Garcia VD, Leone J, Esmeraldo R, Rigotti P, Cambi V, Haas T, 2306 and 2307 study groups.
    Transpl Int; 2007 Jan; 20(1):27-36. PubMed ID: 17181650
    [Abstract] [Full Text] [Related]

  • 4. Everolimus with reduced-dose cyclosporine in de novo renal transplant recipients: Philippine experience.
    Li JT, Danguilan RA, Cabanayan-Casasola CB, Talusan-Tomacruz Y, Ona ET.
    Transplant Proc; 2008 Sep; 40(7):2211-3. PubMed ID: 18790195
    [Abstract] [Full Text] [Related]

  • 5. Conversion to everolimus in maintenance patients--current clinical strategies.
    Pohanka E.
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii24-9. PubMed ID: 16815853
    [Abstract] [Full Text] [Related]

  • 6. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial.
    Salvadori M, Scolari MP, Bertoni E, Citterio F, Rigotti P, Cossu M, Dal Canton A, Tisone G, Albertazzi A, Pisani F, Gubbiotti G, Piredda G, Busnach G, Sparacino V, Goepel V, Messa P, Berloco P, Montanaro D, Veroux P, Federico S, Bartezaghi M, Corbetta G, Ponticelli C.
    Transplantation; 2009 Nov 27; 88(10):1194-202. PubMed ID: 19935373
    [Abstract] [Full Text] [Related]

  • 7. A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine.
    Montagnino G, Sandrini S, Casciani C, Schena FP, Carmellini M, Civati G, Rigotti P, Cossu M, Altieri P, Salvadori M, Federico S, Stefoni S, Cambi V, Albertazzi A, Buoncristiani U, Berloco P, Segoloni G, Boschiero L, Sparacino V, Donati D, Turello E, Dal Canton A, Ponticelli C.
    Transplant Proc; 2005 Mar 27; 37(2):788-90. PubMed ID: 15848532
    [Abstract] [Full Text] [Related]

  • 8. Everolimus versus azathioprine in a cyclosporine and ketoconazole-based immunosuppressive therapy in kidney transplant: 3-year follow-up of an open-label, prospective, cohort, comparative clinical trial.
    Gonzalez F, Espinoza M, Herrera P, Rocca X, Reynolds E, Lorca E, Roessler E, Hidalgo J, Espinoza O.
    Transplant Proc; 2010 Mar 27; 42(1):270-2. PubMed ID: 20172327
    [Abstract] [Full Text] [Related]

  • 9. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J.
    Transplant Proc; 2009 Dec 27; 41(10):4138-46. PubMed ID: 20005355
    [Abstract] [Full Text] [Related]

  • 10. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J, RAD A2420 Study Group.
    Transplantation; 2009 Jul 15; 88(1):69-76. PubMed ID: 19584683
    [Abstract] [Full Text] [Related]

  • 11. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA.
    Transplant Proc; 2012 Jan 15; 44(1):154-60. PubMed ID: 22310603
    [Abstract] [Full Text] [Related]

  • 12. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR, CADENCE Study Group.
    J Heart Lung Transplant; 2008 Feb 15; 27(2):197-202. PubMed ID: 18267227
    [Abstract] [Full Text] [Related]

  • 13. Late acute cardiac allograft rejection: new therapeutic options?
    Schweiger M, Wasler A, Prenner G, Tripolt M, Schwarz M, Tscheliessnigg KH.
    Transplant Proc; 2005 Dec 15; 37(10):4528-31. PubMed ID: 16387161
    [Abstract] [Full Text] [Related]

  • 14. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine.
    Montagnino G, Sandrini S, Iorio B, Schena FP, Carmellini M, Rigotti P, Cossu M, Altieri P, Salvadori M, Stefoni S, Corbetta G, Ponticelli C.
    Nephrol Dial Transplant; 2008 Feb 15; 23(2):707-14. PubMed ID: 17890244
    [Abstract] [Full Text] [Related]

  • 15. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW.
    Transplantation; 2009 Aug 15; 88(3):421-8. PubMed ID: 19667948
    [Abstract] [Full Text] [Related]

  • 16. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A.
    Pape L, Ahlenstiel T, Ehrich JH, Offner G.
    Pediatr Transplant; 2007 May 15; 11(3):291-5. PubMed ID: 17430485
    [Abstract] [Full Text] [Related]

  • 17. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
    Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM.
    Transplantation; 2010 Jul 15; 90(1):31-7. PubMed ID: 20517177
    [Abstract] [Full Text] [Related]

  • 18. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
    Lehmkuhl H, Hetzer R.
    J Heart Lung Transplant; 2005 Apr 15; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
    [Abstract] [Full Text] [Related]

  • 19. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure.
    Lehmkuhl H, Ross H, Eisen H, Valantine H.
    Transplant Proc; 2005 Dec 15; 37(10):4145-9. PubMed ID: 16387066
    [Abstract] [Full Text] [Related]

  • 20. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
    Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A, Calmus Y, Rogiers X, Abecassis M, Freeman R, Sloof M, Roberts J, Fischer L.
    Liver Transpl; 2006 Nov 15; 12(11):1640-8. PubMed ID: 16598777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.